Evaluating a multimodality platform of tissue-, blood-, and advanced imaging-based, predictive biomarkers to neoadjuvant immunotherapy and radiotherapy response in mucosal melanoma
Active Project Grant Awarded Last action
- Award ID
- HT9425261E434
- Recipient
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $559,001
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 1% complete
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded The University of Texas M.D. Anderson Cancer Center $559,001 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to evaluate a multimodality platform of tissue-, blood-, and advanced imaging-based predictive biomarkers to neoadjuvant immunotherapy and radiotherapy response in mucosal melanoma. Work will be performed in Houston, Texas, with a period of performance through October 31, 2028. This award is a Project Grant assistance type. The modification corrected the total award amount listed on the contract line item; all other terms and conditions remain unchanged.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $559,001 |
Quick answers
Who received award HT9425261E434?
HT9425261E434 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by Defense Health Agency (Department of Defense) on November 1, 2026.
How much is award HT9425261E434 worth?
$559,001 has been obligated on HT9425261E434.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award